126338-77-0

Basic information

• Product Name: miramistin
• Synonyms: miramistin;benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium chloride;(S)-benzyl 2-(3-tert-butoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate;miramistin 126338-77-0
• CAS NO: 126338-77-0
• Molecular Formula: C₂₆H₄₇N₂O*Cl
• Molecular Weight: 439.1172
• EINECS: 239-908-9
• Mol File: 126338-77-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: miramistin(CAS DataBase Reference)
• NIST Chemistry Reference: miramistin(126338-77-0)
• EPA Substance Registry System: miramistin(126338-77-0)

Safety Data

• Hazardous Substances Data: 126338-77-0(Hazardous Substances Data)

Usage

Description

Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms, and a clinical profile showing good tolerability.

History

An obscure antiseptic called miramistin, developed by the Soviet space program in the 1950s, may prove to have modern applications in the fight against harmful viruses and bacteria. It is available for clinical use in several prior Soviet bloc countries, but barely known outside of these countries and there is almost no mention of miramistin in the English literature.

Uses

Miramistin is antibacterial surfactant used in stabilization of silver nanoparticles, and various drug delivery. The use of drugs that have powerful antimicrobial action and at the same time are free from side effects, that are caused by antibiotics, plays an important role in solving the problem of wound healing. In addition to antibiotics antiseptics or bacteriolytic enzymes can be used, i.e. drugs that have bactericidal or bacteriostatic effects by lysing the cell wall of microorganisms. Miramistin as an Antimicrobial Component in the Innovative Substance of Chitosan-Miramistin Complex (CMC) for the Treatment of Infected Wounds of Various Genesis

InChI:InChI=1/C26H46N2O/c1-4-5-6-7-8-9-10-11-12-13-17-21-26(29)27-22-18-23-28(2,3)24-25-19-15-14-16-20-25/h14-16,19-20H,4-13,17-18,21-24H2,1-3H3/p+1

Upstream product

• 45267-19-4 myristamidopropyl dimethylamine 
• 104-82-5 4-Methylbenzyl chloride 
• 39669-97-1 N-hexadecanoyl-N',N'-dimethyl-1,3-diaminopropane 
• 100-44-7 benzyl chloride 
• 544-63-8 n-tetradecanoic acid 
• 109-55-7 1-amino-3-(dimethylamino)propane 

Relevant articles and documents

N-(3-(Dimethyl benzyl ammonio)propyl)alkanamide chloride derivatives as corrosion inhibitors for mild steel in 1 M HCl solution: Experimental and theoretical investigation

The effects of N-(3-(dimethyl benzyl ammonio)propyl)lauramide chloride (DMBL), N-(3-(dimethyl benzyl ammonio)propyl)myristamide chloride (DMBM) and N-(3-(dimethyl benzyl ammonio)propyl)palmitamide chloride (DMBP) on the corrosion of mild carbon steel in acidic medium (1.0 M HCl) were investigated using weight loss and electrochemical measurements. The inhibition efficiency was found to be hydrophobicity- and temperature-dependent. Increasing the hydrophobic chain length increased the efficiency due to greater adsorption on the metal surface. The inhibition efficiency is directly proportional to the tested temperature. The electrochemical polarization study revealed that the tested cationic surfactants are mixed-type inhibitors. The Villamil adsorption isotherm is the better-fitted model for describing the adsorption process on the selected steel in 1.0 M HCl medium. The change in the free energy of adsorption of the synthesized cationic surfactants on the metal surface indicates that the adsorption process is chemisorption. Double-layer capacitance values obtained from electrochemical impedance spectroscopy decrease in the presence of the synthesized surfactant. Quantum chemical calculations support the experimental data and the adsorption on the metal surface.

ANTIVIRAL TREATMENT

The present description relates to the use of myramistin, its derivatives and the forms thereof for treating or ameliorating infections caused by enveloped viruses, methods for preparing the compounds and pharmaceutical compositions containing such compounds. In particular the use of myramistin, its derivatives and forms for treating or ameliorating infections caused by coronaviruses. More particularly, the present description relates to the use of myramistin, its derivatives and forms thereof for treating or ameliorating Coronavirus disease 2019 (COVID-19).